Diagnostic and prognostic role of matrix metalloproteinases in patients with chronic obstructive pulmonary disease by Basina, B.O. et al.
 ~ 187 ~ 
The Pharma Innovation Journal 2017; 6(4): 187-189 
      
 
 
 
 
ISSN (E): 2277- 7695 
ISSN (P): 2349-8242 
NAAS Rating 2017: 5.03 
TPI 2017; 6(4): 187-189 
© 2017 TPI 
www.thepharmajournal.com 
Received: 20-02-2017 
Accepted: 21-03-2017 
 
BО Basina 
State Establishment: 
Dnipropetrovsk Medical 
Academy of Health Ministry of 
Ukraine 
 
LІ Konopkina 
State Establishment: 
Dnipropetrovsk Medical 
Academy of Health Ministry of 
Ukraine 
 
GV Kondrateva 
Therapy Department, 
Communal institution 
"Dnipropetrovsk City Clinical 
Hospital № 9" Dnepropetrovsk 
regional council, Dnepropetrovsk 
Ukraine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Correspondence 
BО Basina 
State Establishment: 
Dnipropetrovsk Medical 
Academy of Health Ministry of 
Ukraine 
 
 
 
 
 
 
 
 
 
 
 
Diagnostic and prognostic role of matrix 
metalloproteinases in patients with chronic obstructive 
pulmonary disease 
 
BО Basina, LІ Konopkina and GV Kondrateva 
 
Abstract 
In GOLD 2017 updated report was pointed that lung function level does not depend on patients’ category 
of future risk. That is why continuing of COPD additional risk precursors discussion is still actual. 
COPD is associated with increased numbers of inflammatory cells and fibroblasts and the up-regulation 
of proteases such as matrix metalloproteinases (MMPs) resulting in fibrosis of small airways and 
destruction of the parenchyma. But these markers also constitute innovative direct or indirect targets to 
modify cardiovascular tissue remodelling in atherosclerosis and heart failure. That is why it is important 
to understand could really MMP-2 and MMP-9 be markers of bronchial inflammation including patients 
with COPD. 
The aim of our work was to determine the role of initial and dynamic levels of inflammatory markers 
MMP-2 and MMP-9 as indicators of COPD severity, stability and treatment effectiveness. 
We observe patients with verified stable COPD. The levels of MMP-2 and -9 in plasma were determined 
by ELISA. Investigations were done firstly on screening (visit 1). Then correction of basic anti-
inflammatory treatment was done according to national and European guidelines. Repeated studies were 
done on visit 2 (after 3 months of basic treatment), on visit 3 (after 6 months of basic treatment), on visit 
4 (after 12 months of regular basic treatment). Comparison group was patients with verified cardiac 
disease. Control group was healthy people).  
In general levels of inflammatory markers MMP-2 and MMP-9 in COPD patients on visit 1 were 
significantly higher than in control group, but in subgroups they were almost identical. After 3 months of 
adequate treatment level of MMP-2 dropped slightly, kept at this level for six months, and in one year it 
decreased significantly and reached the level of the control group. On the base of regular treatment both 
MMP-2 and MMP-9 decreased from visit to visit and after 12 month they have been normalized. This 
fact indicates that these markers could be parameters of effective basic treatment in patients with COPD. 
Increasing of such inflammatory biomarkers as MMP-2 and MMP-9 are useful index of COPD which 
indicates on needing of regular basic treatment and dynamic decreasing and normalizing of MMP-2 and 
MMP-9 during basic treatment are signs of successful therapy during their long-term follow-up. 
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1. Introduction 
Chronic obstructive pulmonary disease (COPD) is a debilitating disease that is characterized 
by reduced lung function, breathlessness, decreased productivity, and poor quality of life [13]. 
Currently, COPD is the only major cause of mortality with a rising death rate and it is 
estimated that by 2030 COPD will become the fourth leading cause of death worldwide [9, 10]. 
The natural history of COPD is often marked by periodic exacerbations in which symptoms of 
breathlessness and sputum production worsen acutely, resulting in emergency visits and 
hospitalizations [4, 11, 13]. 
COPD is considered as a chronic inflammatory disease which is non-specific in nature 
involving the airway, lung parenchyma and pulmonary vessels which progressively leads to 
decrease in the airflow. Initiating factors for this inflammatory occurrence, which is not 
normal, are the toxic environmental conditions and the inflammation often remains even after 
eradication of the disturbing agent. This non-specific inflammation can activate a variety of 
inflammatory cells like neutrophils and macrophages and release of various inflammatory 
mediators, such as IL-8, IL-6, and TNF-α est. [3, 7, 12]. These inflammatory mediators destroy 
the lung architecture and also promote the neutrophilic inflammatory response. 
In GOLD 2017 updated report was pointed that lung function level does not depend on 
patients’ category of future risk [5]. That is why continuing of COPD additional risk precursors 
discussion is still actual. 
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COPD is associated with increased numbers of inflammatory 
cells and fibroblasts and the up-regulation of proteases such 
as matrix metalloproteinases (MMPs) resulting in fibrosis of 
small airways and destruction of the parenchyma [6]. But from 
the other side members of the MMP family share sequence 
homology, act on interstitial protein substrates, acutely 
participate in inflammatory processes and chronically mediate 
tissue remodelling. MMPs are important in vascular 
remodelling, not only in the overall vasculature architecture 
but also, more importantly, in the advancing atherosclerotic 
plaque. MMP activation modifies the architecture of the 
plaque and may directly participate in the process of plaque 
rupture. MMPs also participate in cardiac remodelling 
following myocardial infarction and development of dilated 
cardiomyopathy. Soluble MMPs are now potential biomarkers 
in delineating cardiovascular risk for plaque rupture and 
coronary risk. They also constitute innovative direct or 
indirect targets to modify cardiovascular tissue remodelling in 
atherosclerosis and heart failure [8]. That is why it is important 
to understand could really MMP-2 and MMP-9 be markers of 
bronchial inflammation including patients with COPD. 
That is why the aim of our work was to determine the role of 
initial and dynamic levels of inflammatory markers MMP-2 
and MMP-9 as indicators of COPD severity, stability and 
treatment effectiveness. 
 
2. Materials and methods 
We observe 50 patients with verified stable COPD. On 
screening (visit 1) we found that from them 27 patients with 
GOLD III-IV use inadequate and not enouph basic anti-
inflammatory treatment. For these patient correction of basic 
anti-inflammatory treatment was done depending on COPD 
severity according to national and European guidelines [2, 5]. 
After that they form the main group (age – 66, 5±0, 71 years, 
male – 24 (88, 8%), female – 3 (11,2%)). Repeated visits for 
patient of the main group were done after 3 months of basic 
treatment (visit 2), after 6 months of basic treatment (visit 3) 
and after 12 months of regular basic treatment (visit 4). 
The COPD clinical diagnoses were formulated in compliance 
with the recommendations of the Order of the Ministry of 
Healthcare of Ukraine №555 from 27 June 2013 [2]. 
The research of the external respiration function (ERF) with a 
characteristic of the main bronchial obstruction indicators 
(forced vital capacity of lungs (FVC), pulmonary forced 
expiratory volume in 1 second (FEV1)) was conducted using 
computer spirometry with the help of the Master Screen 
Body/Diff device (“Jager”, Germany). The post-
bronchodilator test of bronchial obstruction reversibility was 
made using 400 mcg of salbutamol. 
The levels of MMP-2 and -9 in plasma were determined by 
ELISA [7]. Investigations were done firstly on screening (visit 
1). Repeated studies were done on visit 2 (after 3 months of 
basic treatment), on visit 3 (after 6 months of basic treatment), 
on visit 4 (after 12 months of regular basic treatment). 
Statistical treatment of the research materials was conducted 
using the methods of biometric analysis implemented in the 
EXCEL-2003 (№ 74017-641-9475201-57075), STATISTICA 
6.0 (№ 31415926535897) program packages 1.  
All the examined people gave their consent to clinical 
research.  
Control group was 26 healthy people (age – 58, 9±11,5, male 
– 18 (69,3%), female – 8 (30,7%)).  
 
3. Results 
On visit 1 the condition of patients was stable. Complains and 
results of physical examination corresponded to the stages of 
disease: dyspnea, cough with expectoration of viscous 
sputum, decrease in efficiency. Mean FEV1 (post) was 37, 
5±1,61% pred. 
Levels of inflammatory markers MMP-2 and MMP-9 in 
COPD patients on visit 1 were significantly higher than in 
control group (table 1. 
 
Table 1: Initial levels of biomarkers in patients with COPD 
 
Parameter Main group Control group 
MMP-2, cu 134,8±8,8*# 92,5±4,10 
MMP-9, cu 167,1±18,1*# 103,1±5,55 
Notes:  * - p<0,05 with control group; 
 
According to the analysis of correlation, neither connection 
between the level of MMP-2 and disease severity (r=0,146; 
p=0,213), no between levels of MMP-2 and FEV1 (post) 
(r=0,103; p=0,381) was determined. 
Between the levels of MMP-9, on the one hand, and the 
severity of the disease and the level of FEV1 (post) on the 
other, correlation hasn’t been established (r=0,038; p = 0,748 
and r=-0,078; p=0,510 respectively). At the same time the 
level of MMP-2 had a close correlation with the level of 
MMP-9 (r=0, 4666, p=0, 00003), indicating a unit direction of 
system inflammation markers changes in patients with COPD. 
After 3 months of adequate treatment level of MMP-2 
dropped slightly, kept at this level for six months, and in one 
year it decreased significantly (pv2-v1=0,341; pv3-v2=0,010; pv4-
v3=0.001; pv4-v1=0.000 by the criterion of Wilcoxon) and 
reached the level of the control group (table 2). 
 
Тable 2: Dynamic of biomarkers of patients with COPD 
 
Parameter Main group Control group visit 1 visit 2 visit 3 visit 4 
MMP-2, cu 134,8±8,84 129,2±5,32 128,8±6,17 103,7±4,75* 92,5±4,10 
MMP-9, cu 167,1±18,10 140,8±8,74 145,1±13,70 108,5±4,33* 103,1±5,55 
Notes:  * - p<0,05 with control group; 
 
That is why it should be considered what the dynamic 
changes of plasma levels of MMP-2 can be used as a 
prognostic factor of further progression of COPD during long-
term observation of patients, but only on the base of 
prolonged (per 1 year) adequate treatment. 
Plasma levels of MMP-9 in patients during screening similar 
levels of MMP-2 were significantly higher (almost on 70%) 
than in the control group. Gradually, from one visit to the next 
the level of this parameter was declined steadily (pv2-v1=0,007; 
pv3-v2=0,012; pv4-v3 = 0,001; pv4-v1=0,000 by the criterion of 
Wilcoxon), and only in a year of adequate treatment reached 
the level of the control group (table 2). 
That is why it should be consider what the dynamic changes 
of plasma levels of MMP-9 can be used as a prognostic factor 
for long-term follow-up starting from the earliest stages. 
So on the base of regular treatment both MMP-2 and MMP-9 
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decreased from visit to visit and after 12 month they have 
been normalized (table 2). This fact indicates that these 
markers could be parameters of effective basic treatment in 
patients with COPD. 
 
4. Conclusions 
1. Increasing of such inflammatory biomarkers as MMP-2 
and MMP-9 are useful index of COPD, which indicates 
on needing of regular basic treatment; 
2. Dynamic decreasing and normalizing of MMP-2 and 
MMP-9 during basic treatment are signs of successful 
anti-inflammatory therapy; 
3. Determining of levels of markers of systemic 
inflammation (MMP-2 and -9) can be used as additional 
parameters for assessment of clinical stability in patients 
with COPD during their long-term follow-up. 
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